Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
April 15, 2019 Off

Aptorum Group Limited Reports 2018 Fiscal Year Financial Results and Business Update

By BusinessWire

HONG KONG–(BUSINESS WIRE)–Aptorum Group Ltd. (NASDAQ: APM), a preclinical stage pharmaceutical company developing and commercializing a broad portfolio of projects…

April 15, 2019 Off

Goldfinch Bio Presents Data Enabling the Advancement of Innovative Approaches to the Treatment of Kidney Disease at the International Society of Nephrology World Congress 2019

By BusinessWire

TRPC5 Inhibition with GFB-887 Protects Against Podocyte Injury and Proteinuria Associated with Focal Segmental Glomerulosclerosis and Treatment-resistant Minimal Change Disease…

April 15, 2019 Off

Novocure Publishes 2018 Annual Report Featuring Company’s Vision, Mission and Values

By BusinessWire

The publication of the 2018 Annual Report marks the public debut ofNovocure’s newly defined vision, mission and values. Novocure launchedits vision, mission and values internally to its nearly 600 employees atthe end of 2018.

April 15, 2019 Off

Prospective, Randomized Trial Highlights 5-Year Performance of 2 Standalone Glaukos iStents® vs. Topical Prostaglandin in Newly Diagnosed Glaucoma Patients

By BusinessWire

standalone implantation of two iStent®Trabecular Micro-Bypass Stents in newly diagnosed primary open-angleglaucoma (POAG) eyes achieved a 35.3% reduction in meanintraocular pressure (IOP) to 16.5 mmHg after five years of follow-up.

Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
April 15, 2019 Off

Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

By BusinessWire

The primary endpoint is the percent reduction in urinary oxalate frombaseline to six months. The Company expects to report initialILLUMINATE-B results in mid-2020.

April 15, 2019 Off

Eagle Pharmaceuticals, Inc. Expands Licensing Agreement for BENDEKA™ with Teva Pharmaceuticals International GmbH

By BusinessWire

WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that it has expanded its existing…

April 15, 2019 Off

Zymeworks Opens Phase 2 Clinical Trial for ZW25 in First-Line HER2-Expressing Metastatic Gastroesophageal Cancers

By BusinessWire

VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced it has initiated its…

April 15, 2019 Off

United States Biosimilars Market, Dosage, Price & Clinical Pipeline Outlook 2025 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “US Biosimilars Market, Dosage, Price & Clinical Pipeline Outlook 2025” report has been added to ResearchAndMarkets.com’s offering. “US…

April 15, 2019 Off

Global Specialty Generics Market 2019-2024: Anticipating Growth at a Rate of 11.9%, Aided by the Patent Expiration of a Number of Branded Specialty Drugs – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Specialty Generics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024” report has been added to…

Allele Biotechnology and SCM Lifescience Sign a Joint Research and Development Agreement to Develop iPSC-based Diabetes Treatment
April 15, 2019 Off

Allele Biotechnology and SCM Lifescience Sign a Joint Research and Development Agreement to Develop iPSC-based Diabetes Treatment

By BusinessWire

San Diego-based Allele Biotechnology and Pharmaceuticals, Inc.,officially announced a joint research and development agreement withSouth Korea’s SCM Lifescience Co., Ltd., for the development of diabetestherapies using pancreatic beta cells derived from induced pluripotentstem cells (iPSCs).

Posts pagination

Previous 1 … 3,275 3,276 3,277 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine